Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.57 EUR
−111.83 M EUR
58.62 M EUR
80.99 M
About POSEIDA THERAPEUTICS INC
Sector
Industry
CEO
Kristin Yarema
Website
Headquarters
San Diego
Founded
2014
FIGI
BBG00VYKFR67
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2RZ is 9.24 EUR — it has increased by 0.93% in the past 24 hours. Watch POSEIDA THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange POSEIDA THERAPEUTICS INC stocks are traded under the ticker 2RZ.
2RZ stock is 3.18% volatile and has beta coefficient of 3.55. Track POSEIDA THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is POSEIDA THERAPEUTICS INC there?
Today POSEIDA THERAPEUTICS INC has the market capitalization of 888.98 M, it has increased by 0.46% over the last week.
Yes, you can track POSEIDA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
POSEIDA THERAPEUTICS INC is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
2RZ earnings for the last quarter are 0.19 EUR per share, whereas the estimation was −0.37 EUR resulting in a 150.30% surprise. The estimated earnings for the next quarter are −0.28 EUR per share. See more details about POSEIDA THERAPEUTICS INC earnings.
POSEIDA THERAPEUTICS INC revenue for the last quarter amounts to 64.44 M EUR, despite the estimated figure of 14.59 M EUR. In the next quarter, revenue is expected to reach 28.98 M EUR.
2RZ net income for the last quarter is 18.17 M EUR, while the quarter before that showed −29.29 M EUR of net income which accounts for 162.05% change. Track more POSEIDA THERAPEUTICS INC financial stats to get the full picture.
No, 2RZ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 21, 2025, the company has 330.00 employees. See our rating of the largest employees — is POSEIDA THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. POSEIDA THERAPEUTICS INC EBITDA is −51.22 M EUR, and current EBITDA margin is −294.41%. See more stats in POSEIDA THERAPEUTICS INC financial statements.
Like other stocks, 2RZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade POSEIDA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So POSEIDA THERAPEUTICS INC technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating POSEIDA THERAPEUTICS INC stock shows the buy signal. See more of POSEIDA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.